HTGMQ vs. A, MTD, ILMN, WAT, AVTR, RVTY, BIO, BIO.B, BRKR, and TXG
Should you be buying HTG Molecular Diagnostics stock or one of its competitors? The main competitors of HTG Molecular Diagnostics include Agilent Technologies (A), Mettler-Toledo International (MTD), Illumina (ILMN), Waters (WAT), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), and 10x Genomics (TXG). These companies are all part of the "analytical instruments" industry.
HTG Molecular Diagnostics vs.
HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Agilent Technologies had 26 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 26 mentions for Agilent Technologies and 0 mentions for HTG Molecular Diagnostics. Agilent Technologies' average media sentiment score of 0.48 beat HTG Molecular Diagnostics' score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the news media.
Agilent Technologies has a consensus target price of $143.62, suggesting a potential upside of 6.77%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than HTG Molecular Diagnostics.
87.4% of Agilent Technologies shares are held by institutional investors. 2.6% of HTG Molecular Diagnostics shares are held by insiders. Comparatively, 0.3% of Agilent Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Agilent Technologies has higher revenue and earnings than HTG Molecular Diagnostics.
Agilent Technologies received 863 more outperform votes than HTG Molecular Diagnostics when rated by MarketBeat users.
Agilent Technologies has a net margin of 19.80% compared to HTG Molecular Diagnostics' net margin of 0.00%. Agilent Technologies' return on equity of 25.43% beat HTG Molecular Diagnostics' return on equity.
HTG Molecular Diagnostics has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Summary
Agilent Technologies beats HTG Molecular Diagnostics on 13 of the 15 factors compared between the two stocks.
Get HTG Molecular Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HTGMQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HTGMQ vs. The Competition
HTG Molecular Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:HTGMQ) was last updated on 12/22/2024 by MarketBeat.com Staff
Free HTGMQ Stock Alerts